CAMZYOS - (2.5MG, 5MG, 10MG, 15MG ; Capsule)

Generic Name	MAVACAMTEN	**Innovator**	BRISTOL MYERS SQUIBB
Dosage	2.5MG, 5MG, 10MG, 15MG ; Capsule	**Branded US Sales**	More Than $1000 mn
Probable FTF	More Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.